By / December 30, 2019

Colombia to begin exporting Medcann’s medical cannabis

Advances for Medcann’s medical cannabis have been tried in Colombia with the production of certified medicines and phytotherapeutic products for export.

Medcann will begin the production of cannabis-based medicines, approved under the Good Manufacturing Practices certification. Expanding the international market for medical cannabis is the objective of the company.

In order to find more on this subject, one potentially useful cannabis investing tool is the app. You can find more information about cannabis markets and other important news in the cannabis sector in the app.

Medcann’s medical cannabis goals for 2020

The goal for the first months of 2020, according to Medcann’s medical cannabis spokespeople, is to conquer markets with great potential such as Brazil and Peru, among others.

It signed an agreement of intent through which it may exclusively negotiate the purchase of a drug production laboratory with a Good Manufacturing Practice certification.

“We are proud to be able to reiterate our commitment to medical research and to the highest quality processes in Colombia so that the country can continue to bet on the development of the medical cannabis industry and take the great international leap forward,” said John Ruiz, president of the company.

Medcann features high capacity laboratories

a cargo ship representing shipments of medcann's medical cannabis
Medcann hopes to be ahead of the international market by exporting medical cannabis products. (Source)

Ruiz also said that this laboratory has the capacity to process that extracted oil into a pill and a cream according to its medical use.

“This allows us to export the final medicine to the Brazilian and Peruvian markets, guaranteeing that the entire value chain stays in Colombia; it begins with the cultivation and even the process of transforming the cannabis flower into a final product,” he added.

The executive for Medcann’s medical cannabis highlighted this major step in the international market after achieving Colombia’s first records of psychoactive varieties of cannabis in 2018.

The first of Medcann’s medical cannabis production facilities

“At this moment there is no laboratory with certification that is dedicated to the production of cannabis medicines currently in Colombia,” said Ruiz. “That is why this is the first time that this export path has been opened, taking into account that the country has traditionally been exporting raw material without processing. In this case, we are going to have the possibility of exporting a product with all the added value.”


(Featured image by CBD Infos via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in RCNRadio, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.